318 related articles for article (PubMed ID: 26271606)
1. Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.
Kumar SK; Ma E; Engebretson AE; Buadi FK; Lacy MQ; Dispenzieri A; Duh MS; Lafeuille MH; Lefebvre P; Cheng WY; Dea K; Rembert D; Patt D; Niculescu L; Quick M; Rajkumar SV
Leukemia; 2016 Apr; 30(4):995-8. PubMed ID: 26271606
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.
Jacobus SJ; Rajkumar SV; Weiss M; Stewart AK; Stadtmauer EA; Callander NS; Dreosti LM; Lacy MQ; Fonseca R
Blood Cancer J; 2016 Jul; 6(7):e448. PubMed ID: 27471864
[No Abstract] [Full Text] [Related]
4. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
5. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A; Parikh K; Ni Q; Abouzaid S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
Hornberger J; Rickert J; Dhawan R; Liwing J; Aschan J; Löthgren M
Eur J Haematol; 2010 Dec; 85(6):484-91. PubMed ID: 20846301
[TBL] [Abstract][Full Text] [Related]
7. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
[TBL] [Abstract][Full Text] [Related]
8. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
Usmani SZ; Sexton R; Ailawadhi S; Shah JJ; Valent J; Rosenzweig M; Lipe B; Zonder JA; Fredette S; Durie B; Hoering A; Bartlett B; Orlowski RZ
Blood Cancer J; 2015 Aug; 5(8):e334. PubMed ID: 26252787
[No Abstract] [Full Text] [Related]
9. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.
Ludwig H; Greil R; Masszi T; Spicka I; Shpilberg O; Hajek R; Dmoszynska A; Paiva B; Vidriales MB; Esteves G; Stoppa AM; Robinson D; Chaturvedi S; Ataman O; Enny C; Feng H; van de Velde H; Viterbo L
Br J Haematol; 2015 Nov; 171(3):344-54. PubMed ID: 26153365
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.
Sidra G; Williams CD; Russell NH; Zaman S; Myers B; Byrne JL
Haematologica; 2006 Jun; 91(6):862-3. PubMed ID: 16769594
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.
Cavo M; Pantani L; Pezzi A; Petrucci MT; Patriarca F; Di Raimondo F; Marzocchi G; Galli M; Montefusco V; Zamagni E; Gamberi B; Tacchetti P; Brioli A; Palumbo A; Sonneveld P
Leukemia; 2015 Dec; 29(12):2429-31. PubMed ID: 26442610
[No Abstract] [Full Text] [Related]
12. Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
Jung SH; Choi HJ; Shin MG; Lee SS; Hwang EC; Jung TY; Cho MS; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
Ann Hematol; 2016 Oct; 95(10):1645-51. PubMed ID: 27365142
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG
Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
Mai EK; Bertsch U; Dürig J; Kunz C; Haenel M; Blau IW; Munder M; Jauch A; Schurich B; Hielscher T; Merz M; Huegle-Doerr B; Seckinger A; Hose D; Hillengass J; Raab MS; Neben K; Lindemann HW; Zeis M; Gerecke C; Schmidt-Wolf IG; Weisel K; Scheid C; Salwender H; Goldschmidt H
Leukemia; 2015 Aug; 29(8):1721-9. PubMed ID: 25787915
[TBL] [Abstract][Full Text] [Related]
15. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
[TBL] [Abstract][Full Text] [Related]
16. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Leiba M; Kedmi M; Duek A; Freidman T; Weiss M; Leiba R; Nagler A; Avigdor A
Br J Haematol; 2014 Sep; 166(5):702-10. PubMed ID: 24861981
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
Scott LJ; Lyseng-Williamson KA
BioDrugs; 2011 Oct; 25(5):333-7. PubMed ID: 21942918
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide in multiple myeloma: current role and future directions.
Zeldis JB; Knight RD; Jacques C; Tozer A; Bizzari JP
Expert Opin Pharmacother; 2010 Apr; 11(5):829-42. PubMed ID: 20210686
[TBL] [Abstract][Full Text] [Related]
20. Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.
Cejalvo MJ; de la Rubia J
Future Oncol; 2015; 11(11):1643-58. PubMed ID: 25857329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]